Therese Rydell Joins Amferia as Director of Quality and Regulatory Affairs
Amferia AB is happy to welcome Therese Rydell as the Director of Quality and Regulatory Affairs. Therese has extensive background from quality and regulatory operations in med-tech industry bringing knowledge and experience for the continued growth of Amferia. The company is now expanding the animal health business to new markets and pursuing regulatory approval in the US.
Therese has a solid background in QA/RA from global companies in the Medtech field spanning over 10 years in leading roles such as; Global QA Engineer at Mölnlycke HealthCare, Quality and Regulatory Manager at Integration Diagnostics Sweden and most recently as Senior Regulatory Affairs Specialist, International Registrations at Cochlear Bone Anchored Solutions. At Amferia, Therese will head up the QA/RA operations and enable bringing high quality products to patients. Therese’s extensive knowledge in the life science industry will be important for Amferia’s scale-up journey in both human and animal wound care.
Anand Kumar Rajasekharan, CEO of Amferia − “We are delighted to welcome Therese, whose knowledge of quality and regulatory affairs strengthens Amferia’s position as a competent and cutting-edge SME. We look forward to jointly achieve the upcoming key milestones such as the expanding our animal health business to new markets and pursuing FDA and CE regulatory processes for human health.
Therese Rydell− “Amferia is an exciting company to join and build. The technology offers a paradigm shift in wound care with nontoxic properties still killing bacteria, even the resistant ones. In a world where antimicrobial resistance is an increasing challenge to humanity, I am glad to be a part of reducing that threat".
For more information, please contact:
Anand Kumar Rajasekharan,
CEO, Amferia, +46 76 298 12 38
Amferia's antimicrobial amphiphilic hydrogel kills bacteria, even resistant bacteria without harming the body. The material was developed through several years of research in collaboration with Swedish Chalmers University of Technology. Amferia's innovative, anti-microbial solution can be used on wide-ranging wounds, from simple skin injuries to post-operative wounds, chronic wounds, and trauma and burn wounds. The first product from this technology platform is a wound-care dressing for dry-to-low exuding wounds. Amferia has ongoing clinical investigations in Europe and is seeking CE marking and FDA clearance for human application.
Read more about the products, team, technology and publications at www.amferia.com
